Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding phase II study of norursodeoxycholic acid in non-alcoholic fatty liver disease
2013-004605-38Phase 2Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) (3 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Change in serum alanine aminotransferase (ALT). Started Dec 2014; status: completed.
02
Drugs
norursodeoxycholic acid
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2013-004605-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004605-38.